Povetacicept

Phase 3Protein / enzyme

Vertex Pharmaceuticals

Povetacicept is one of 72 small molecule programs targeting Glomerular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glomerular DiseaseActive, not recruiting

Membranous NephropathyActive, not recruiting

Primary Membranous NephropathyRecruiting

Myasthenia Gravis, GeneralizedRecruiting

NephropathyActive, not recruiting

Glomerular DiseasePhase 1/Phase 2

Active, not recruiting

Membranous NephropathyPhase 2/Phase 3

Active, not recruiting

Primary Membranous NephropathyPreclinical

Recruiting

Myasthenia Gravis, GeneralizedPhase 2

Recruiting

NephropathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

131 competitors in Nephropathy

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Phase 3

7 2

Zemplar

AbbVie

Phase 3

1 3

Simulect

Novartis

Phase 3

1 4

Ultomiris

AstraZeneca

Phase 3

—5

Acetadote

AArbor Pharmaceuticals, Inc.

Phase 3

3 6

Tekturna

Tibotec Pharmaceuticals, Ireland

Phase 3

1 7

Aurlumyn

BBTG International Inc.

Phase 3

1 8

Campath

GGenzyme, a Sanofi Company

Phase 3

1 9

Epoetin Beta

Roche

Phase 3

1 10

Darbepoetin

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Nephropathy

NCT06564142

Phase 1/2Active, not recruiting

Glomerular Disease

NCT05732402

Q4 2028

PreclinicalRecruiting

Primary Membranous Nephropathy

NCT07204275

Q1 2029

Phase 2Recruiting

Myasthenia Gravis, Generalized

NCT07501702

Clinical

Trials by Indication[1]

Nephropathy1 trial

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

Active, not recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 3·NCT06564142·605 enrolled

Immune1 trial

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias

Active, not recruiting·AAlpine Immune Sciences, Inc.·Phase 1/2·NCT05757570·30 enrolled

Glomerular Disease1 trial

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

Active, not recruiting·AAlpine Immune Sciences, Inc.·Phase 1/2·NCT05732402·72 enrolled

Primary Membranous Nephropathy1 trial

A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy

Recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Preclinical·NCT07204275·176 enrolled

Myasthenia Gravis, Generalized1 trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis

Recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT07501702·30 enrolled

1 more indication

Unspecified1 trial

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT07010406·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Povetacicept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Povetacicept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Povetacicept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Vertex Pharmaceuticals

Povetacicept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Q1 2029

Trials by Indication[1]

Nephropathy1 trial

Immune1 trial

Glomerular Disease1 trial

Primary Membranous Nephropathy1 trial

Myasthenia Gravis, Generalized1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News